You are here

Contact:
Wanda Moebius
202-434-7240
wmoebius@advamed.org
May 22, 2013

AdvaMedDx Supports Diagnostics Payment Reform Legislation

WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, a division of the Advanced Medical Technology Association (AdvaMed) focused on diagnostics policy matters, released the following statement on the introduction by Rep. Peter J. Roskam (R-Ill.) of HR 2085, the “Diagnostic Innovation Testing and Knowledge Advancement Act of 2013”:

“We applaud Congressman Roskam for his leadership in recognizing the crucial role of diagnostics in patient care and the need to ensure continued innovation in this area. We also commend the cosponsors of this important bipartisan legislation – Richard Neal (D-Mass.), Ron Kind (D-Wis.), Erik Paulsen (R-Minn.), Leonard Lance (R-N.J.), Brett Guthrie (R-Ky.) and Patrick Tiberi (R-Ohio). Diagnostic tests account for only two percent of Medicare spending but influence up to 70 percent of health care decisions, leading to better patient outcomes and often reducing health care costs.

“Unfortunately, current Medicare payment policies for diagnostics are severely flawed and do not recognize the value that modern diagnostic tests provide to health care. Furthermore, the Medicare fee schedule for diagnostic tests has been adjusted for inflation only five times in the past 23 years.

“HR 2085 – which is similar to legislation introduced in the 112th Congress (HR 6446) – represents an important first step toward improving the archaic process for determining Medicare payment rates for new tests.

“This bill would establish new payment-setting criteria incorporating elements of patient value and the impact of diagnostics, including revolutionary genetic tests, on quality care. These changes would support more timely patient access to advanced diagnostics by better recognizing the contributions these tests make to better health outcomes and our health care system.”

# # #

AdvaMedDx member companies produce innovative, safe and effective in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, promote wellness, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMedDx is dedicated to the issues facing in vitro diagnostic companies both in the United States and abroad.